DOCSLIB.ORG

Pharmacotherapy of Attention-Deficit/Hyperactivity 49 Disorder Across the Life Span

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacotherapy of Attention-Deficit/Hyperactivity 49 Disorder Across the Life Span Pharmacotherapy of Attention-Deficit/Hyperactivity 49 Disorder across the Life Span Jefferson B. Prince, MD, Timothy E. Wilens, MD, Thomas J. Spencer, MD, and Joseph Biederman, MD KEY POINTS www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformation • Attention-deficit/hyperactivity disorder (ADHD) is a forHeathcareProfessionals/ucm165858.htm for the most common disorder in children, adolescents, and recent recommendations by the Food and Drug Administra- adults. tionA] [FD about monitoring for children and http://www.fda .gov/drugs/drugsafety/ucm279858.htm for the most recent • While the phenotype of ADHD changes across the recommendations about monitoring for adults). Clinicians life span, ADHD persists in many children, and patients/families should select an initial treatment, either adolescents, and adults. a stimulant or a non-stimulant; decide on a target dose (either • Formulations of stimulant and non-stimulant absolute or weight-based) titration schedule; and decide how medications are Food and Drug Administration- to monitor tolerability and response to treatment (using rating approved as pharmacological treatments for ADHD in scales, anchor points, or both). Patients should be educated children, adolescents, and adults. about the importance of adherence, safely maintaining medi- • Co-morbid psychiatric and learning disorders are cations (e.g., as in college students), and additional types of common in patients with ADHD across the life span. treatment (e.g., coaching and organizational help) that may be helpful. • When treating ADHD and co-morbid disorders, clinicians must prioritize and treat the most severe condition first, and regularly re-assess the symptoms STIMULANTS of ADHD and the co-morbid disorder. For over 60 years stimulants have been used safely and effec- tively in the treatment of ADHD21 and they are among the most well-established treatments in psychiatry.22,23 The stimu- lants most commonly used include methylphenidate (MPH), a mixture of amphetamine salts (MAS) and dextroampheta- OVERVIEW mine (DEX). The recent development of various novel delivery systems has significantly advanced the pharmacotherapy of Attention-deficit/hyperactivity disorder (ADHD) is a common ADHD (see Table 49-1 for a list of these medications). psychiatric condition shown to occur in 3% to 10% of school- age children worldwide, up to 8% of adolescents and up to 4% of adults.1–5 The classic triad of impaired attention, impul- Pharmacodynamic Properties of Stimulants sivity, and excessive motor activity characterizes ADHD, Stimulants increase intra-synaptic concentrations of dopamine although many patients may manifest only inattentive symp- (DA) and norepinephrine (NE).24–27 MPH primarily binds to toms.6,7 ADHD usually persists, to a significant degree, from theA D transporter protein (DAT), blocking the re-uptake of childhood through adolescence and into adulthood.8,9 Most DA, increasing intra-synaptic DA.25,27 While amphetamines children, adolescents, and adults with ADHD suffer significant diminish pre-synaptic re-uptake of DA by binding to DAT, functional impairment(s) in multiple domains,10 as well as these compounds also travel into the DA neuron, promoting co-morbid psychiatric or learning disorders.5,11–18 release of DA from reserpine-sensitive vesicles in the pre- Studies demonstrate that ADHD is frequently co-morbid synaptic neuron.25,26 In addition, stimulants (amphetamine > with oppositional defiant disorder (ODD), conduct disorder MPH) increase levels of NE and serotonin (5-HT) in the inter- (CD), multiple anxiety disorders (panic disorder, obsessive- neuronal space.24Although group studies comparing MPH and compulsive disorder [OCD], tic disorders), mood disorders amphetamines generally demonstrate similar efficacy,19,20 their (e.g., depression, dysthymia, and bipolar disorder [BPD]), pharmacodynamic differences may explain why a particular learning disorders (e.g., auditory processing problems and patienty ma respond to, or tolerate, one stimulant preferen- dyslexia), and substance use disorders (SUDs) and often com- tially over another. It is necessary to appreciate that while the plicates the development of patients with autism spectrum efficacy of amphetamine and MPH is similar, their potency disorders (ASDs). Co-morbid psychiatric, learning, and devel- differs, such that 5 mg of amphetamine is approximately opmental disorders need to be assessed in all patients with equally potent to 10 mg of MPH. ADHD and the relationship of these symptoms with ADHD 1,19,20 delineated. Methylphenidate Before using medications, clinicians should complete a through clinical evaluation that includes a complete history As originally formulated, MPH was produced as an equal of symptoms, a differential diagnosis, a review of prior mixture of d,l-threo-MPH and d,l-erythro-MPH. The erythro assessments/treatments, a medical history, and a description isomers of MPH appear to produce side effects, and thus MPH of current physical symptoms (including questions about the isw no manufactured as an equal racemic mixture of d,l-threo- physical history, including either a personal or family history MPH.28 Behavioral effects of immediate-release MPH peak 1 of cardiovascular symptoms or problems). Before treatment to 2 hours after administration, and tend to dissipate within with medications, it is usually important to measure baseline 3 to 5 hours. After oral administration immediate-release levels of height, weight, blood pressure, and pulse and to MPH is readily absorbed, reaching peak plasma concentra- monitor them over the course of treatment (see http:// tion in 1.5 to 2.5 hours, and has an elimination half-life of 538 Downloaded for Rohul Amin ([email protected]) at Uniformed Services Univ of the Health Sciences from ClinicalKey.com by Elsevier on September 29, 2018. For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved. Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder across the Life Span 539 TABLE 49-1 Available FDA-approved Treatments for Attention-Deficit/Hyperactivity Disorder 49 Usual Absolute and (Weight- FDA-approved Generic Name Duration of based) Dosing Maximum Dose (Brand Name) Formulation and Mechanism Activity How Supplied Range for ADHD MPH (Ritalin)* Tablet of 50 : 50 racemic mixture 3–4 hours 5, 10, and 20 mg (0.3–2 mg/kg/day) 60 mg/day d,l-threo-MPH tablets Dex-MPH Tablet of d-threo-MPH 3–5 hours 2.5, 5, and 10 mg (0.15–1 mg/kg/day) 20 mg/day (Focalin)* tablets (2.5 mg Focalin equivalent to 5 mg Ritalin) MPH (Methylin)* Tablet of 50 : 50 racemic mixture 3–4 hours 5, 10, and 20 mg (0.3–2 mg/kg/day) 60 mg/day d,l-threo-MPH tablets MPH-SR Wax-based matrix tablet of 50 : 50 3–8 hours 20 mg tablets (0.3–2 mg/kg/day) 60 mg/day (Ritalin-SR)* racemic mixture d,l-threo-MPH Variable (amount absorbed appears to vary) MPH (Metadate Wax-based matrix tablet of 50 : 50 3–8 hours 10 and 20 mg (0.3–2 mg/kg/day) 60 mg/day ER)* racemic mixture d,l-threo-MPH Variable tablets (amount absorbed appears to vary) MPH (Methylin Hydroxypropyl methylcellulose 8 hours 10 and 20 mg (0.3–2 mg/kg/day) 60 mg/day ER)* base tablet of 50 : 50 racemic tablets mixture d,l-threo-MPH; no 2.5, 5, and 10 mg preservatives chewable tablets 5 mg/5 ml and 10 mg/5 ml oral solution MPH (Ritalin LA)* Two types of beads give bimodal 8 hours 20, 30, and 40 mg (0.3–2 mg/kg/day) 60 mg/day delivery (50% immediate-release capsules; can be and 50% delayed-release) of sprinkled 50 : 50 racemic mixture d,l-threo-MPH D-MPH (Focalin Two types of beads give bimodal 12 hours 5, 10, 15, 20, 25, 0.15–1 mg/kg/day 30 mg/day in XR) delivery (50% immediate-release 30, 35, and 40 mg youth; 40 mg/ and 50% delayed-release) of capsules day in adults d-threo-MPH MPH (Metadate Two types of beads give bimodal 8 hours 20 mg capsule; can (0.3–2 mg/kg/day) 60 mg/day CD)* delivery (30% immediate-release be sprinkled and 70% delayed-release) of 50 : 50 racemic mixture d,l-threo-MPH MPH (Daytrana)* MPH transdermal system 12 hours (patch 10, 15, 20, and 0.3–2 mg/kg/day 30 mg/day worn for 9 hours) 30 mg patches MPH (Concerta)* Osmotic pressure system delivers 12 hours 18, 27, 36, and (0.3–2 mg/kg/day) 72 mg/day 50 : 50 racemic mixture 54 mg caplets d,l-threo-MPH MPH (Quillivant Extended-release liquid 12 hours 25 mg/5 ml (0.3–2 mg/kg/day) 60 mg/day XR) AMPH† (Dexedrine d-AMPH tablet 4–5 hours 5 mg tablets (0.15–1 mg/kg/day) 40 mg/day Tablets) AMPH† d-AMPH tablet 4–5 hours 5 and 10 mg tablets (0.15–1 mg/kg/day) 40 mg/day (Dextrostat) AMPH† (Dexedrine Two types of beads in a 50 : 50 8 hours 5, 10, and 15 mg (0.15–1 mg/kg/day) 40 mg/day Spansules) mixture short and delayed- capsules absorption of d-AMPH Mixed salts of Tablet of d,l-AMPH isomers (75% 4–6 hours 5, 7.5, 10, 12.5, 15, (0.15–1 mg/kg/day) 40 mg/day AMPH† d-AMPH and 25% l-AMPH) 20, and 30 mg (Adderall) tablets Mixed salts of Two types of beads give bimodal At least 8 hours 5, 10, 15, 20, 25, (0.15–1 mg/kg/day) 30 mg/day in AMPH*‡ delivery (50% immediate-release (but appears to and 30 mg children (Adderall-XR) and 50% delayed-release) of last much longer capsules; can be Recommended 75 : 25 racemic mixture in certain sprinkled dose is d,l-AMPH patients) 20 mg/day in adults Continued on following page Downloaded for Rohul Amin ([email protected]) at Uniformed Services Univ of the Health Sciences from ClinicalKey.com by Elsevier on September 29, 2018.
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Piperidine Derivatives Piperidinderivate Derives De Piperidine
    (19) TZZ_¥Z_T (11) EP 1 669 350 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/58 (2006.01) C07D 401/06 (2006.01) 29.02.2012 Bulletin 2012/09 C07D 401/14 (2006.01) C07D 401/02 (2006.01) C07D 401/12 (2006.01) C07D 409/12 (2006.01) (2006.01) (2006.01) (21) Application number: 04787951.5 A61K 31/4545 A61K 31/496 A61K 31/454 (2006.01) A61K 31/4523 (2006.01) A61K 31/4535 (2006.01) A61K 31/506 (2006.01) (22) Date of filing: 21.09.2004 A61P 43/00 (2006.01) A61P 3/04 (2006.01) A61P 3/10 (2006.01) A61P 5/00 (2006.01) A61P 3/06 (2006.01) A61P 19/06 (2006.01) A61P 9/10 (2006.01) A61P 9/04 (2006.01) A61P 9/12 (2006.01) (86) International application number: PCT/JP2004/013768 (87) International publication number: WO 2005/028438 (31.03.2005 Gazette 2005/13) (54) PIPERIDINE DERIVATIVES PIPERIDINDERIVATE DERIVES DE PIPERIDINE (84) Designated Contracting States: • TOKITA, Shigeru, AT BE BG CH CY CZ DE DK EE ES FI FR GB GR c/o Tsukuba Research Institute HU IE IT LI LU MC NL PL PT RO SE SI SK TR Tsukuba-shi, Designated Extension States: Ibaraki 3002611 (JP) LT LV • KANATANI, Akio, c/o Tsukuba Research Institute (30) Priority: 22.09.2003 JP 2003330758 Tsukuba-shi, Ibaraki 3002611 (JP) (43) Date of publication of application: 14.06.2006 Bulletin 2006/24 (74) Representative: Rollins, Anthony John et al Merck Sharp & Dohme Limited (73) Proprietor: MSD K.K.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • (Esi Scheme) Laxminagar, Ajmer Road, Jaipur-302006
    DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref. No. F434/ESI/Store/LabEmp/2017/5540 Dated:01/11/2017 E- Tender Document For “E- Tender forAnalysis of Drugs, Cotton, Gauzes, Bandage & Other items” For The Office of the Director cum Ex-officio Dy. Secretary, Medical & Health Services ESI Scheme Rajasthan, Laxmi Nagar, Ajmer Road, Jaipur & attached ESIS Institutions in Rajasthan ( for the period of two years from the date of award. ) ( Non-transferable ) Price of Tender Document Rs. 2000/- Last date & time of submission of Technical & Financial Bids is 11.12.17 at 1:30 pm Date & time of online opening of Technical Bid is 11.12.17 at 3:00 pm Visit Us At http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in, www.health.rajasthan.gov.in/esi Our Address: DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 1/71 DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref.No.F434/ESI/Store/LabEmp/2017/ 5540 Dated:01/11/2017 E-bids in two separate bids (Technical & Financial) for the Empanelment of Analytic Testing Laboratories For The Test and Analysis of drugs, cotton, bandage, gauze & other items. Brief Details of E-Tender Estimated Cost : Rs 50 lacs EMD (Bid Security)Rs 100000/- RISL processing fees Rs 1000/- Cost of the Tender Document Rs 2000/- Performance Security 5% of contract value Services Required:- The service of analysis of drugs, cotton, gauze, bandages & other items are required in the office of the Director cum Ex- officio Dy.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Pharmacological Treatment Options for Alcohol Use Disorder*
    Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2015;28:283-300 Editorial / Editoryal DOI: 10.5350/DAJPN20152804001 Pharmacological Treatment Cuneyt Evren1, Muge Bozkurt2 1Assoc. Prof. Dr., 2Psychiatrist, Bakirkoy Training and Options for Alcohol Use Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Disorder* Istanbul - Turkey Address reprint requests to / Yazışma adresi: Assoc. Prof. Dr. Cuneyt Evren, Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Istanbul, Turkey Phone / Telefon: +90-212-409-1515/2111, Fax / Faks: +90-212-409-1590, E-mail address / Elektronik posta adresi: [email protected] *Abridged version of the “Therapeutic Guideline for Alcohol Use Disorder” prepared by the Working Group Therapeutic Guideline for Alcohol Use Disorder. PHARMACOLOGICAL TREATMENT assess information obtained from studies regarding OPTIONS FOR ALCOHOL USE DISORDER drug treatments used in clinical practice today, which are summarized in Table 1. However, when examining Alcohol Use Disorder (AUD) and other alcohol- study results for pharmacological treatments, we related health problems are a significant public health immediately have to remember that all of those issue all over the world. The World Health Organization (WHO) reports that each year 3.3 million people lose Table 1: Drugs used for the therapy of alcohol use their lives due to harmful alcohol use, with 5.9% of all disorder (AUD) deaths being related to alcohol consumption (1). It has Drugs for AUD approved in Turkey been estimated that in 2010, the economic burden of Disulfiram Naltrexone alcohol-related costs was 155.8 billion Euro, of which Acamprosate 60% were connected to alcohol addiction (2).
    [Show full text]
  • A2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet Al
    US009078919B2 a2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet al. (45) Date of Patent: *Jul. 14, 2015 (54) MICRO-RNAS OF THE MIR-15 FAMILY 2005/0182011 Al 8/2005 Olson etal. MODULATE CARDIOMYOCYTE SURVIVAL 2006/0058266 Al 3/2006 Manoharan etal. AND CARDIAC REPAIR 2006/0105360 Al 5/2006 Croce etal. 2006/0165659 Al 7/2006 Croceet al. 2006/0185027 Al 8/2006 Bartelet al. (71) Applicant: The Board of Regents, The University 2006/0189557 Al 8/2006 Slack et al. of Texas System, Austin, TX (US) 2006/0247193 Al 11/2006 Taira et al. 2006/0252722 Al 11/2006 Lollo et al. (72) Inventors: Eric N. Olson, Dallas, TX (US); Eva 2007/0026403 Al 2/2007 Hatzigeorgiouetal. 2007/0054287 Al 3/2007 Bloch van Rooij, Utrecht (NL) 2007/0213292 Al 9/2007 Stoffel et al. 2007/0259827 Al 11/2007 Aronin et al. (73) Assignee: The Board of Regents, the University 2007/0287179 Al 12/2007 Tuschletal. of Texas System, Austin, TX (US) 2007/0292878 Al 12/2007 Raymond. 2008/0050744 Al 2/2008 Brownetal. (*) Notice: Subject to any disclaimer, the term of this 2008/0176766 Al 7/2008 Brownetal. 2008/0220423 Al 9/2008 Molleret al. patent is extended or adjusted under 35 2009/0053718 Al 2/2009 Naguibnevaetal. U.S.C. 154(b) by 0 days. 2009/0092980 Al 4/2009 Arenzet al. 2009/0131356 Al 5/2009 Baderet al. This patent is subject to a terminal dis- 2009/0176723 Al 7/2009 Brownetal. claimer. 2009/0214477 Al 8/2009 Betzet al.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett Et Al
    USO08080578B2 (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett et al. (45) Date of Patent: *Dec. 20, 2011 (54) METHODS FOR TREATMENT WITH 5,998.458. A 12/1999 Bristow ........................ 514,392 BUCNDOLOL BASED ON GENETIC 6,004,744. A 12/1999 Goelet et al. ...... 435/5 6,013,431 A 1/2000 Söderlund et al. 435/5 TARGETING 6,156,503 A 12/2000 Drazen et al. ..... ... 435/6 6,221,851 B1 4/2001 Feldman ... 51446 (75) Inventors: Stephen B. Liggett, Clarksville, MD 6,316,188 B1 1 1/2001 Yan et al. .......................... 435/6 6,365,618 B1 4/2002 Swartz ... 514,411 (US); Michael Bristow, Englewood, CO 6,498,009 B1 12/2002 Liggett ............................. 435/6 (US) 6,566,101 B1 5/2003 Shuber et al. 435,912 6,586,183 B2 7/2003 Drysdale et al. .................. 435/6 (73) Assignee: The Regents of the University of 6,784, 177 B2 8/2004 Cohn et al. 514,248 Colorado, a body corporate, Denver, 6,797.472 B1 9/2004 Liggett ......... ... 435/6 6,821,724 B1 1 1/2004 Mittman et al. ... 435/6 CO (US) 6,861.217 B1 3/2005 Liggett ......... ... 435/6 7,041,810 B2 5/2006 Small et al. ... ... 435/6 (*) Notice: Subject to any disclaimer, the term of this 7, 195,873 B2 3/2007 Fligheddu et al. ... 435/6 patent is extended or adjusted under 35 7,211,386 B2 5/2007 Small et al. ....... ... 435/6 7,229,756 B1 6/2007 Small et al.
    [Show full text]
  • Toxicological Profile for Carbon Tetrachloride
    CARBON TETRACHLORIDE 27 3. HEALTH EFFECTS 3.1 INTRODUCTION The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of carbon tetrachloride. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­ observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear.
    [Show full text]
  • Alcool Expertise Collective Alcool Effets Sur La Santé Effets Sur La Santé
    Expertise collective Alcool Expertise collective Alcool Effets sur la santé Effets sur la santé Les effets de l’alcool sur la santé font aujour- d’hui encore l’objet d’une importante recherche. Les travaux nous apprennent que ces effets dépendent non seulement des niveaux de consommation, mais également de la suscepti- bilité du consommateur et de ses modalités de consommation. Effets cardiovasculaires délé- tères ou bénéfiques, cancers, hépatopathies, atteintes des systèmes nerveux central ou péri- phérique, toutes les conséquences d’une consommation d’alcool ont été passées au crible dans le cadre de cette expertise collective de l’Inserm effectuée à la demande de la Cnamts, du CFES et de la Mildt. Comment traduire les données récentes en Effets sur la santé termes d’information et de messages de préven- tion ? Les conclusions de cette expertise invitent à adapter ces messages aux différentes popula- tions (jeunes, adultes, personnes âgées) et aux situations particulières (femmes enceintes, Alcool conduite automobile, professions à risque, situations sanitaires à risque…). Prix 180 FF € 27,44 Expertise collective ISBN 2-85598-797-0 ISSN 1264-1782 www.inserm.fr Cet ouvrage présente les travaux du groupe d’experts réunis par l’Inserm dans le cadre de la procédure d’expertise collective, pour répondre aux questions posées par le Comité français d’éducation pour la santé (CFES), la Caisse nationale d’assurance maladie des travailleurs salariés (Cnamts) et la Mission interministérielle de lutte contre la drogue et la toxicomanie (Mildt) concer- nant les effets de la consommation d’alcool sur la santé. Il s’appuie sur les données scientifiques disponibles en date du premier semes- tre 2001.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information C om pany 300 North Z eeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800 521-0600 Order Number 9120692 Part 1. Synthesis of fiuorinated catecholamine derivatives as potential adrenergic stimulants and thromboxane A 2 antagonists. Part 2.
    [Show full text]